Close

Judge Accepts Amgen's (AMGN) $762M Plea in Civil Liability Case

Go back to Judge Accepts Amgen's (AMGN) $762M Plea in Civil Liability Case

Amgen (AMGN) To Pay $612 Million to Resolve Liabilities on Promotional Practices

December 19, 2012 1:31 PM EST

Amgen (NASDAQ: AMGN) today announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations.

Amgen will pay approximately $612 million to resolve its civil liability related to certain promotional practices related to the drugs Aranesp® (darbepoetin alfa), EPOGEN® (epoetin alfa), NEUPOGEN® (Filgrastim), Neulasta® (pegfilgrastim), Enbrel® (etanercept) and Sensipar® (cinacalcet) as alleged in the unsealed qui tam complaints and $150 million... More